Business Wire

McChrystal Group Expands European Presence, Opening London Office

Del

McChrystal Group, a global advisory services and leadership development firm, has opened a new office in Central London, England. The firm is opening this location in response to continued demand for its services in the U.K. and European markets.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171009005458/en/

Chris Fussell, co-founder of McChrystal Group, former US Navy SEAL, bestselling author (Photo: Busin ...

Chris Fussell, co-founder of McChrystal Group, former US Navy SEAL, bestselling author (Photo: Business Wire)

The office will be headed by Mr. Ash Alexander-Cooper OBE, a Director at McChrystal Group, with experience expanding the company’s offerings and building clients’ leadership teams. He retired from a British Defence career in 2016 after 22 years’ service, having spent 82 months deployed on operations in complex and hostile environments. Since joining McChrystal Group in 2016, he has led successful client engagements in North America, Europe, Asia, and South America, specialising in health, infrastructure, mining, and retail sectors.

“We are excited about the opportunity to grow our European footprint and strengthen our relationships across the globe. Our ‘team of teams’ approach has proved exceptionally successful with our clients globally, and we will continue our focus on superior service to our EMEA clients from our new base in London,” said General (Ret.) Stan McChrystal, who founded McChrystal Group in 2011.

“We are thrilled to formally expand our reach into Europe and beyond, at a time when the environment has rarely been more uncertain or complex,” said Mr. Alexander-Cooper. “With Brexit looming, there exists an even greater need for organisational adaptability and effective leadership. McChrystal Group has the necessary experience, tools, and an outstanding team to partner with and support clients during these challenging times,” he added.

McChrystal Group’s “team of teams” approach is outlined in the New York Times bestselling book Team of Teams: New Rules of Engagement for a Complex World (2015; Portfolio/Penguin Random House) which was co-authored by General McChrystal and his former aide-de-camp and McChrystal Group co-founder, Chris Fussell. Mr. Fussell was commissioned as a U.S. Naval Officer in 1997, and spent the next 15 years on U.S. Navy SEAL teams, leading elements in combat zones around the world. The book has since been widely embraced in the business world as a roadmap for combining the agility, adaptability, and cohesion of a small team with the power and resources of a giant organisation.

Mr. Fussell has now published the sequel to Team of Teams, the Wall Street Journal bestseller One Mission: How Leaders Build a Team of Teams (2017; Macmillan). The sequel offers practical case studies and a tangible guide for organisations to tear down silos, improve collaboration, and avoid turf wars. Both books are available in the U.S., U.K., and Europe.

Mr. Fussell and Mr. Alexander-Cooper are both available for media interviews in London from 9 October to 13 October. To book either of them, please reach out to the media contacts below.

ABOUT McCHRYSTAL GROUP

McChrystal Group, founded by General (Ret.) Stanley McChrystal in 2011, is a global advisory services and leadership development firm composed of a diverse mix of professionals from the military, academic, business, and intelligence sectors who specialise in transforming stagnant and siloed organisations into cohesive, adaptable “teams of teams.” The firm works with firms across the globe from its offices in Alexandria, Virginia, USA, and London, England. For information about working with McChrystal Group, please contact Ash Alexander-Cooper for Europe or contact@mcchrystalgroup.com globally.

Contact information

McChrystal Group
Dina Finnegan, +1 703-282-2516
dina.finnegan@mcchrystalgroup.com
or
Kathleen Hatfield, +1 305-934-6696
kathleen.hatfield@mcchrystalgroup.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an